| CXSL2100099 | GZR18 | GZR-18 | Injection | Biological Products(1) | New Drug Application | 2021-03-24 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | In Review | 2021-03-23 | view |
| CYSB2000073 | 重组甘精胰岛素注射液 | insulin glargine | Injection | Biological Products | Supplementary Application | 2020-04-22 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | Certificate Issued | 2020-07-16 | view |
| CYSB2000360 | 重组甘精胰岛素注射液 | insulin glargine | Injection | Biological Products(原7) | Supplementary Application | 2020-12-18 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | In Review | 2020-12-16 | view |
| CXSS1400003 | 门冬胰岛素30注射液 | Insulin aspart protamine recombinant;insulin aspart recombinant | Injection | Biological Products(15) | New Drug Application | 2014-12-25 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | Certificate Issued | 2018-06-28 | view |
| CYSB1700216 | 重组甘精胰岛素注射液 | insulin glargine | Injection | Biological Products | Supplementary Application | 2018-06-15 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | Certificate Issued | 2019-06-26 | view |
| CYSB2000182 | 精蛋白锌重组赖脯胰岛素混合注射液（25R） | | Injection | Biological Products | Supplementary Application | 2020-07-04 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | Certificate Issued | 2020-12-21 | view |
| CXSL1400054 | 精蛋白锌重组赖脯胰岛素混合注射液(40R) | | Injection | Biological Products(6) | New Drug Application | 2014-10-11 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | Certificate Issued | 2016-06-20 | view |
| CYSB2100018 | 甘精胰岛素注射液 | insulin glargine | Injection | Biological Products | Supplementary Application | 2021-01-11 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | In Review | 2022-01-19 | view |
| CYSB1500535 | 重组甘精胰岛素注射液 | insulin glargine | Injection | Biological Products | Supplementary Application | 2016-09-18 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | Certificate Issued | 2017-09-14 | view |
| CYSB2000359 | 重组甘精胰岛素注射液 | insulin glargine | Injection | Biological Products(原7) | Supplementary Application | 2020-12-18 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | In Review | 2020-12-16 | view |
| CXSS1400002 | 门冬胰岛素30注射液 | Insulin aspart protamine recombinant;insulin aspart recombinant | Injection | Biological Products(15) | New Drug Application | 2014-12-25 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | Certificate Issued | 2020-12-10 | view |
| CYSB1700181 | 重组甘精胰岛素注射液 | insulin glargine | Injection | Biological Products | Supplementary Application | 2017-11-16 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | In Review | 2017-11-14 | view |
| CYSB2000096 | 重组赖脯胰岛素注射液 | insulin lispro | Injection | Biological Products | Supplementary Application | 2020-05-18 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | Certificate Issued | 2020-07-27 | view |
| CYSB2100017 | 赖脯胰岛素注射液 | insulin lispro | Injection | Biological Products | Supplementary Application | 2021-01-11 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | In Review | 2022-01-19 | view |
| CXSS1400015 | 精蛋白重组人胰岛素注射液(预混30R) | | Injection | Biological Products(15) | New Drug Application | 2015-01-19 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | Certificate Issued | 2021-05-31 | view |
| CYSB2000015 | 重组赖脯胰岛素注射液 | insulin lispro | Injection | Biological Products | Supplementary Application | 2020-02-14 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | Certificate Issued | 2020-03-26 | view |
| CXSL1400055 | 门冬胰岛素50注射液 | Insulin aspart protamine recombinant;insulin aspart recombinant | Injection | Biological Products(15) | New Drug Application | 2014-10-11 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | Certificate Issued | 2016-05-19 | view |
| CXSS1600003 | 门冬胰岛素注射液 | insulin aspart | Injection | Biological Products(15) | New Drug Application | 2017-06-02 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | Certificate Issued | 2020-05-19 | view |
| CYSB2000095 | 重组赖脯胰岛素注射液 | insulin lispro | Injection | Biological Products | Supplementary Application | 2020-05-18 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | Certificate Issued | 2020-07-27 | view |
| CYSB2100016 | 赖脯胰岛素注射液 | insulin lispro | Injection | Biological Products | Supplementary Application | 2021-01-11 | 甘李药业股份有限公司 | Gan & Lee Pharmaceuticals | In Review | 2022-01-19 | view |
